Status:
COMPLETED
Beneficial Effect of Intravenous Magnesium Sulphate in Term Neonates With Hypoxic Ischemic Encephalopathy(HIE)
Lead Sponsor:
Services Institute of Medical Sciences, Pakistan
Conditions:
HIE
Eligibility:
All Genders
Up to 6 years
Phase:
PHASE2
Brief Summary
Neonatal mortality rate is the highest in Pakistan. And Birth Asphyxia is one of the main reversible causes. Outcomes related to birth asphyxia can be improved, if intervention done in time with prope...
Detailed Description
Some studies showed positive results if given within 6 hours of birth asphyxia, whereas some are not supportive. But still less know about this drug, especially in low income countries. Objective of t...
Eligibility Criteria
Inclusion
- After informed consent, any child who is term, inborn or out born fulfilling the definition of hypoxic ischemic encephalopathy according to history, apgar or scoring system and reaching within 6 hours of delivery in nursery department of pediatric medicine unit-II, Services Hospital, Lahore
Exclusion
- Preterm Syndromic/dysmorphic child Term child with HIE and arriving after 6 hours of life. Term child with unrelated co morbidities eg congenital heart defects, Renal failure etc
Key Trial Info
Start Date :
May 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04705142
Start Date
May 1 2019
End Date
December 30 2020
Last Update
January 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Services Institute of Medical Sciences, Lahore
Lahore, Punjab Province, Pakistan, 54000